Earnings Call Summary | EHealth(EHTH.US) Q2 2024 Earnings Conference
Earnings Call Summary | EHealth(EHTH.US) Q2 2024 Earnings Conference
Adjusted The following is a summary of the EHealth, Inc. (EHTH) Q2 2024 Earnings Call Transcript:
以下是易康公司（EHTH）2024年第二季度業績會的摘要:
Financial Performance:
金融業績：
eHealth reported a Q2 total revenue of $65.9 million, a slight decline of 1% year-over-year.
Excluding tail revenue, total revenue for the quarter increased 13% year-over-year.
Adjusted EBITDA improved by $6.5 million year-over-year, excluding impact of restructuring and impairment charges and tail revenue.
GAAP net loss was $28 million, compared to a loss of $23.5 million the previous year.
易康報告Q2總營業收入爲6590萬美元，同比略微下降1%。
除去尾部收入，本季度總營業收入同比增長13%。
除去重組和減值費用和尾部收入的影響，調整後的EBITDA同比增加了650萬美元。
GAAP淨虧損爲2800萬美元，相比上一年的2350萬美元虧損有所增加。
Business Progress:
業務進展：
eHealth experienced a 16% increase in Medicare submissions year-over-year.
The company launched several new customer retention strategies and saw improvements in Medicare segment profit by $6.1 million year-over-year, excluding tail revenue.
eHealth's carrier-dedicated platform, Amplify, saw strong enrollment volumes and conversion rates, and onboarded a new customer during Q2.
易康的醫保提交數量同比增加了16%。
公司推出了多種新的客戶保留策略，並且除去尾部收入，醫保部門利潤同比增加了610萬美元。
易康的專用載體平台Amplify在第二季度表現強勁，註冊數量和轉化率高，併成功在Q2引進了一位新客戶。
Opportunities:
機會：
The anticipated Medicare plan changes provide an opportunity for eHealth to drive strong consumer demand to its platform during the enrollment season.
預期的醫保計劃變更爲易康在報名季節期間推動強勁的消費者需求提供了機會。
Risks:
風險：
The upcoming CFO transition and CEO's planned retirement might impact the company's operational continuity and leadership stability.
即將進行的CFO轉型和CEO計劃退休可能會對公司的運營連續性和領導穩定性產生影響。
More details: eHealth IR
更多詳情請參考易康IR。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息，請參閱IR網站。本文只是爲投資者提供參考，沒有任何指導或推薦建議。